Clinical Relevance of Circulating Nucleic Acids in Blood of Prostate Cancer Patients by Heidi Schwarzenbach
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Clinical Relevance of Circulating Nucleic Acids 
in Blood of Prostate Cancer Patients 
Heidi Schwarzenbach 
Department of Tumour Biology, Center of Experimental Medicine, University Medical 
Center Hamburg-Eppendorf, Hamburg  
Germany  
1. Introduction 
The prostate carcinoma is the most frequent cancer of men. In contrast to the second most lung 
cancer, there are no self-caused risk factors. Hence, the cause of prostate cancer is still 
unknown. Nevertheless, there are men having a higher risk to get prostate cancer than other 
men. In the early stage the disease is symptom-free, whereas in the advanced stage complaints, 
such as difficulty in urination, miction pains and bone pains may occur. If symptoms emerge, 
metastases, primarily in the local lymph nodes or the bone marrow, may frequently be 
diagnosed (Knudsen & Vasioukhin, 2010). A successive treatment is only possible if the 
tumour tissue did not metastasize. So far, the early diagnosis of prostate cancer is difficult and 
challenging. Usually, the diagnosis is associated with several prostate biopsies. The current 
standard screening method is carried out by measuring the level of the prostate specific 
antigen (PSA) in blood, combined with a digital rectal examination (Jones & Koeneman, 2008). 
However, in men starting from 50 years an increased PSA value can indicate benign prostatic 
hyperplasia or prostate cancer. Moreover, the increase in the blood level of PSA (biochemical 
recurrence) cannot differentiate between local and metastatic tumours (Jansen et al., 2008). 
Therefore, an increased PSA value has to be absolutely clarified. Moreover, most prostate 
tumours are initially sensitive to androgen ablation therapy. If the treatment is not curative, 
patients can become hormonal refractory. Although docetaxel-based chemotherapy remains 
the standard treatment for hormone-refractory prostate cancer (Tannock et al., 2004), few 
predictive factors for the efficacy of chemotherapy has been reported. Thus, new strategies of 
early prostate cancer diagnosis and prognosis should be developed. 
During the last years, nucleic acids, such as DNA, RNA and microRNAs (miRs), which 
circulate in high concentrations in blood of cancer patients, have gained increasing attention 
and their potential value as possible biomarkers has been highlighted. To avoid tumour 
biopsies by invasive methods, cell-free nucleic acids in plasma or serum could serve as a 
“liquid biopsy” useful for diagnostic application of prostate cancer. This minimally invasive 
procedure delivers the possibility of taking repeated blood samples, consequently allowing the 
changes in cell-free nucleic acids to be traced during the natural course of the disease or during 
anti-cancer treatment. The current chapter focuses on the clinical utility of cell-free nucleic 
acids as blood-based biomarkers for prostate cancer, considering the genetic and epigenetic 
alterations that can be detected in circulating DNA as well as the modulated levels of miRs. 
The relationship between cell-free nucleic acids and micrometastatic cells is also discussed. 
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As a result of increased apoptotic and necrotic cell deaths during carcinogenesis, nucleic 
acids are released into the blood circulation (Jahr et al., 2001). The concentrations of these 
tumour-associated, cell-free nucleic acids may associate with tumour load and malignant 
progression towards metastatic relapse, and discriminate between men with localized 
prostate cancer and benign prostatic hyperplasia (Muller et al., 2006). Analyses of cell-free 
DNA allow the detection of tumour-specific genetic and epigenetic alterations of genes 
relevant to prostate cancer development and progression. In particular, DNA 
hypermethylation of pi-class glutathione S-transferase genes may be an additional blood-
based biomarker relevant for prostate cancer. Combining the scrutiny of tumour-specific 
blood DNA with the screening of disseminated tumour cells - the putative precursor cells of 
metastases - in blood and bone marrow, may provide additional information for monitoring 
tumour progression and metastases, and support the molecular staging of prostate tumours 
(Schwarzenbach & Pantel, 2008; Ellinger et al., 2011). The approach could also favour an 
early intervention to therapy, and contribute to identify those patients with a higher risk for 
a recurrence. In addition, miRs involved in the regulatory networks of protein expression by 
binding to and repressing the translation of specific target mRNAs are frequently 
deregulated in cancer (Ozen et al., 2008). Recent measurements have shown that these small 
RNA molecules may become potential blood-based biomarkers for prostate cancer patients 
(Wang et al., 2009). 
2. History and biology of circulating nucleic acids 
In 1948, Mandel and Métais described the presence of cell-free nucleic acids in human 
blood for the first time (Mandel & Métais, 1948). This attracted little attention in the 
scientific community, and it was not until 1994 that the importance of circulating nucleic 
acids was recognized as a result of the detection of mutated RAS gene fragments in blood 
of cancer patients (Sorenson et al., 1994; Vasioukhin et al., 1994). Two years later, also 
microsatellite alterations on cell-free DNA could be detected in the blood (Nawroz et al., 
1996). These findings were the beginning of increasing attention that has during the past 
decade been paid to cell-free nucleic acids, such as DNA and RNA, which are present at 
high concentrations in blood of cancer patients. The first study on cell-free DNA in blood 
of prostate cancer was published in 2004, and showed higher plasma DNA levels in 
patients with metastatic disease than in patients with clinically localized prostate cancer 
(Jung et al., 2004). 
Investigations of DNA fragmentation patterns in blood of cancer patients revealed that this 
DNA shows an apoptotic as well as a necrotic pattern (Jahr et al., 2001), as a result of cell 
death of tumour and wild type cells or of active secretion. It is unknown, whether besides 
the increased cell turnover in cancer patients, the clearance time also contributes to the 
higher levels of cell-free DNA. The degradation of cell-free DNA from the bloodstream 
occurs usually rapidly, e.g., the half-life time of fetal DNA in blood of mothers after delivery 
was approximately 16 minutes (Lo et al., 1999). Conversely, miRs appear highly stable, as 
they are small nucleotide fragments resistant to enzymes and incorporated in microvesicles 
(Kosaka et al., 2010). The nuclease activity in blood may be one of the important factors for 
the turnover of cell-free nucleic acids. However, this area of physiology remains unclear and 
needs further examination. The elimination of cell-free nucleic acids occurs by renal and 
hepatic mechanisms (Botezatu et al., 2000; Minchin et al., 2001).  
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3. Quantification of cell-free genomic and mitochondrial DNA 
In blood of patients with prostate cancer, increased levels of cell-free DNA consisting of 
genomic and mitochondrial DNA have been assessed by different fluorescence-based methods 
using PicoGreen or SybrGreen and quantitative real-time PCR amplifying different genes. It is 
difficult to compare the DNA concentrations reported by various groups of investigators, since 
different techniques and plasma or serum were used. Plasma DNA seems to reflect the in vivo 
concentrations of cell-free DNA better than serum DNA. In respect to the quantification of 
DNA released from haematopoietic cells during the clotting process, the DNA concentrations 
in serum were essentially higher than those in plasma (Lee et al., 2001). Table 1 summarizes 
the diagnostic and prognostic relevance of cell-free DNA in plasma and serum of prostate  
 
n>50 
Cell-free 
nucleic acids 
Diagnostic Prognostic Refs. 
64 DNA quantification x  Altimari et al., 2008 
78 DNA quantification x  Boddy et al., 2005 
91 DNA quantification  x Jung et al., 2004 
161 DNA quantification x  Chun et al., 2006 
192 DNA quantification  x Bastian et al., 2007 
252 DNA quantification x  Gordian et al., 2010 
168 PTGS2 DNA x x Ellinger et al., 2008a 
75 mitochondrial DNA  x Mehra et al., 2007 
100 mitochondrial DNA  x Ellinger et al., 2008c 
57 microsatellite assay x  Schwarzenbach et al., 2007 
65 microsatellite assay x  Muller et al., 2006 
71 microsatellite assay x  Muller et al., 2008 
81 microsatellite assay x  Schwarzenbach et al., 2009 
83 microsatellite assay x  Sunami et al., 2009 
230 microsatellite assay x  Schwarzenbach et al., 2008 
76 DNA methylation  x Okegawa et al., 2010 
83 DNA methylation x  Sunami et al., 2009 
85 DNA methylation x  Bastian et al., 2005 
210 DNA methylation x  Bastian et al., 2008 
91 DNA methylation x  Schwarzenbach et al., 2010 
142 DNA methylation x  Payne et al., 2009 
168 DNA methylation x  Ellinger et al., 2008b 
171 DNA methylation x  Ellinger et al., 2008a 
61 Histone modification x  Deligezer et al., 2010 
50 miR 21 x  Zhang et al., 2010 
51 miR 21, 141, 221 x  Yaman Agaoglu et al., 2011 
71 miR 375, 141 x  Brase et al., 2010 
Table 1. Detection of cell-free DNA with its genetic and epigenetic alterations and 
quantification of miRs in patients with prostate cancer  
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cancer patients, and represents different forms of cell-free nucleic acids analyzed in studies 
including more than 50 prostate cancer patients (n>50). This table is based on my review of 
publications deemed as significant clinical translational events. 
3.1 Cell-free genomic DNA 
The first systematic investigation on the quantitative changes of circulating DNA in prostate 
cancer patients was the study by Jung et al. (Jung et al., 2004). In this publication increased 
DNA concentrations were only observed in patients with lymph node and distant 
metastases. Whereas the DNA concentrations measured in patients with organ-confined 
cancer did not differ from those in healthy controls, the concentrations in patients with 
benign prostate hyperplasia (BPH) were elevated. These enquiries suggested that high DNA 
levels in patients with prostatic diseases can be considered neither as cancer-specific nor as 
sensitive marker for prostate cancer. In contrast to the lacking diagnostic relevance, the 
prognostic value of DNA concentrations as survival indicator could be shown and was 
comparable with the established marker PSA or with a reliable bone marker like 
osteoprotegerin (Jung et al., 2004). Besides, Boddy et al. found higher DNA levels in prostate 
cancer patients than in either healthy controls or men at low risk of having prostate cancer 
(low PSA or normal digital rectal examination). However, the elevated levels were not of 
diagnostic value during the management of prostate cancer, because those men with benign 
prostatic pathology had significantly higher DNA yields than the prostate cancer group 
(Boddy et al., 2005). Although the diagnostic relevance of cell-free DNA levels has been 
reported by other studies, most of those studies have not examined benign prostatitis. My 
laboratory compared the plasma DNA levels in prostate cancer and BPH patients and 
showed that the preoperative DNA level is a highly accurate and informative predictor in 
uni- and multivariate models for the presence of prostate cancer on needle biopsy. The 
median plasma concentration of cell-free DNA was 267 ng/mL in men with BPH versus 709 
ng/mL in men with prostate cancer, and could consequently discriminated between men 
with localized prostate cancer and BPH (Chun et al., 2006). In another study, the median 
serum DNA concentration of prostate cancer patients was 5.3 ng/mL. Concentrations of 
≥5.75 ng/mL were associated with an increased risk of PSA recurrence within 2 years of 
radical prostatectomy (Bastian et al., 2007). A cut off value of 8 ng/mL of plasma DNA was 
reported to discriminate between patients and healthy control subjects with a sensitivity of 
80% and specificity of 82%, but in comparison to the other studies, these DNA 
measurements were very low. In addition, high levels of cell-free DNA correlated with 
pathologic tumour stage (Altimari et al., 2008). It was also reported, that patients with PSA 
of ≤10 ng/mL and cell-free DNA of > 180 ng/mL were at increased risk for prostate cancer 
compared with those with DNA of ≤180 ng/mL. Summing up, these findings show that cell-
free DNA improved the specificity of prostate cancer screening and might, therefore, reduce 
the number of unnecessary prostate biopsies (Gordian et al., 2010).  
Ellinger et al. designed a study to evaluate the apoptosis index which expresses the ratio of 
prostaglandin-endoperoxide synthase 2 (PTGS2) to Reprimo DNA fragments. 
Concentrations of apoptotic PTGS2 fragments discriminated between BPH and prostate 
cancer patients with a sensitivity of 88% and specificity of 64%, whereas the apoptosis index 
was more specific with 82% but less sensitive with 70%. Following radical prostatectomy 
apoptotic PTGS2 fragments and the apoptosis index correlated with PSA recurrence 
(Ellinger et al., 2008a).  
www.intechopen.com
 
Clinical Relevance of Circulating Nucleic Acids in Blood of Prostate Cancer Patients 
 
119 
3.2 Cell-free mitochondrial DNA 
Apart from genomic DNA, mitochondrial DNA can also be quantified in blood of prostate 
cancer patients. Indicating the different nature of these circulating DNA types, the levels of 
cell-free genomic and mitochondrial DNA did not correlate (Mehra et al., 2007). In contrast 
to two copies of genomic DNA, a single cell contains up to several hundred copies of 
mitochondrial DNA. Whereas genomic DNA circulates mostly in a cell-free form and has 
also been isolated from microvesicles (which include exosomes and apoptotic bodies 
(Orozco & Lewis, 2010), mitochondrial DNA circulates mainly in microvesicles (Chiu et al., 
2003). As diagnostic and prognostic marker in prostate cancer patients the amplification of 
mitochondrial nucleic acids has been reported to display increased sensitivity and 
specificity over genomic DNA. Advanced prostate cancer patients with high plasma 
mitochondrial nucleic acids (DNA and RNA) had a poorer survival than patients with low 
levels. Thus, mitochondrial RNA seems to be a strong predictor of overall survival and an 
independent prognostic factor for cancer-related death (Mehra et al., 2007). A further study 
showed that circulating mitochondrial DNA levels did not distinguish between prostate 
cancer and BPH patients. However, there was a significant increase in short mitochondrial 
DNA fragments including apoptotic DNA in patients with early PSA recurrence after 
radical prostatectomy (Ellinger et al., 2008c). 
4. Genetic analyses of cell-free DNA 
The development of prostate cancer is associated with genetic and epigenetic alterations 
accumulating during tumour growth and disease progression. The loss of particular 
sequences encoding for tumour suppressors can lead to the loss of a tumour-protective 
function of the appropriate gene product. Such gene defects may have an influence on cell 
cycle, cell adhesion or apoptosis. Cytogenetic and molecular genetic methods have 
identified numerous tumour-associated chromosomal regions playing a role in the 
tumourigenesis of prostate cancer.  
Genetic alterations on cell-free DNA, including loss of heterozygosity (LOH), can be detected 
by PCR-based fluorescence microsatellite assays using microsatellite DNA (Fig. 1). 
Microsatellite DNA consists of short highly repetitive DNA sequences and is widely spread in 
the genome. In maternal and paternal chromosomes microsatellite DNA frequently differs in 
its length, corresponding to the number of repetitive sequences. This allows the separation of 
both alleles by gel or capillary electrophoresis and their analyses. Although similar plasma- 
and serum-based detection methods have been used, a great variability in detection of LOH on 
cell-free DNA has been reported. Besides the concordance of tumour-related LOH on cell-free 
DNA in blood with LOH on DNA from matched primary tumour tissues, discrepancies have 
also been found (Fleischhacker & Schmidt, 2007). These contradictory LOH data derived from 
blood and tumour tissue and the low incidence of LOH on cell-free DNA have been explained 
in part by technical problems and the dilution of tumour-associated cell-free DNA in blood by 
DNA released from normal cells (Muller et al., 2008; Schwarzenbach et al., 2008; Schmidt et al., 
2006). Moreover, abnormal proliferation of benign cells, due to inflammation or tissue repair 
processes, also leads to an increase in apoptotic cell death, the accumulation of small, 
fragmented DNA in blood and the masking of LOH (Schulte-Hermann et al., 1995). In spite of 
these evident restrictions, plasma DNA may be a more appropriate source for genetic analyses 
than tumour tissue because blood may be a pool of tumour-specific DNA derived from focal 
areas of the heterogeneous primary prostate tumour harbouring different genetic alterations 
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(Bonkhoff & Remberger, 1998). Furthermore, the possibility of taking repeated blood samples 
allows tracing genetic alterations during treatment. 
 
 
Fig. 1. Detection of genetically and epigenetically altered DNA and quantification of 
microRNAs in blood  
To detect LOH on cell-free DNA, extracted DNA is amplified in a PCR-based fluorescence 
microsatellite analysis using a gene-specific primer set binding to tumour suppressor genes. 
The fluorescence-labeled PCR products can be separated by capillary gel electrophoresis 
and detected by a fluorescence laser. In the diagram (left) the abscissa indicates the length of 
the PCR product, whereas the ordinate gives information on the fluorescence intensity 
represented as peaks. The upper and lower part of the diagram show the PCR products 
derived from wild type DNA (from leukocytes) and plasma DNA, respectively. As depicted 
by the two peaks of the amplified wild type DNA, both alleles are intact, whereas the lower 
peak of the PCR product derived from the plasma DNA shows LOH (indicated by an 
arrow). To detect cell-free methylated DNA, extracted DNA is denatured and treated by 
sodium bisulfite. In a methylation-sensitive PCR the modified DNA is amplified with gene-
specific primers. Since sodium bisulfite converts unmethylated cytosine residues into uracil, 
in contrast to methylated cytosine, the methylation pattern can be determined by DNA 
sequencing (middle). To quantify miRs, extracted total RNA is subscribed into cDNA which 
is then amplified with miR-specific primers in a quantitative real-time PCR reaction (right). 
To investigate the potential significance of LOH on cell-free DNA, my laboratory compared 
the LOH incidence at 5 polymorphic microsatellite markers in plasma of prostate cancer and 
BPH patients. We found that LOH was frequently detected in prostate cancer patients and 
rarely observed in BPH patients indicating for the first time that microsatellite analysis 
using plasma DNA may be an interesting tool for molecular screening of prostate cancer 
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patients (Muller et al., 2006). When the LOH frequency in blood plasma was compared with 
the incidence in tumour tissues and bone marrow aspirates of prostate cancer patients 
without clinical signs of overt metastases, we found that the concordance of LOH 
aberrations was 65% in blood plasma and 55% in bone marrow plasma samples with the 
analogous primary tumours. Our findings show that at least part of the cell-free DNA in 
blood and bone marrow may originate from the primary tumour. The subsets of LOH in 
blood and bone marrow plasma, which were not concordant with the detected tumour 
alterations, might be due to the known heterogeneity of the prostate tumours and the 
presence of wild type DNA in the plasma (Schwarzenbach et al., 2007). Moreover, we 
analyzed LOH at a panel of 13 polymorphic microsatellite markers in a large cohort of 230 
prostate cancer and 43 BPH patients. The overall incidence was significantly higher in primary 
tumours (34%) than in blood plasma samples from prostate cancer patients (11%). Although 
LOH was also found in BPH plasma samples, its frequency of 2% was low. The highest 
concordance of LOH between tumour and plasma samples was 83% at the chromosomal locus 
8p21 (Schwarzenbach et al., 2008). These findings provoked us to optimize the DNA extraction 
method to increase the detection rate of LOH on cell-free DNA in blood. 
Comparing two DNA extraction techniques, Wang et al. demonstrated that the 
guanidine/Promega resin method significantly enhanced the sensitivity of detection of k-
ras mutations on circulating serum DNA from colorectal cancer patients in comparison to 
the commonly used QIAamp DNA blood kit from the manufacturer Qiagen (Wang et al., 
2004). The most abundant DNA detected in the Qiagen preparation was high-molecular-
weight DNA, in contrast to mono-, di-, and trinucleosomal DNA isolated by the 
guanidine/Promega resin method (Wang et al., 2004). These findings lead to the 
suggestion that tumour-specific DNA might be enriched in the DNA portion containing 
shorter fragments, and to optimize the PCR-based fluorescence microsatellite method, we 
established a method to fractionate plasma DNA in short and long fragments (Muller et 
al., 2008). For preparation of the first fraction containing high-molecular-weight DNA, we 
isolated plasma DNA by Qiagen DNA Mini columns, and for the second fraction 
containing low-molecular-weight DNA, we used the flow-through of the first fraction and 
purified it on Promega columns. Because low-molecular-weight DNA may interfere with 
assay sensitivity, it was necessary to improve the assay conditions. By adding 
tetramethylammonium chloride (TMAC) (Hung et al., 1990; Chevet et al., 1995) as a 
general and essential enhancer to the PCR reactions, our results could be stabilized and 
ambiguous allelic losses could be largely avoided. Our data showing an enhancement of 
the detection rate of LOH in the low-molecular-weight plasma DNA from prostate cancer 
patients, point out that tumour-specific plasma DNA seems to mainly consist of short 
fragments. However, for practical plasma-based diagnostic tests the presence of LOH in 
both fractions should be considered (Muller et al., 2008).  
Table 1 summarizes the diagnostic relevance of genetically altered DNA in plasma and 
serum of prostate cancer patients. 
5. Epigenetic analyses of cell-free DNA 
The epigenetic process includes DNA methylation and chromatin histone modifications. In 
chromosomal regions of tumour-associated genes epigenetic alterations may affect 
important regulatory mechanisms for the pathogenesis of malignant transformation (Klose 
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& Bird, 2006). Inactivation of tumour suppressor genes by promoter hypermethylation is 
thought to play a crucial role in this process (Esteller & Herman, 2002). DNA methylation of 
the cytosine base in CpG dinucleotides, which are found as isolated or clustered CpG 
islands, induces gene repression by inhibiting the access of transcription factors to their 
binding sites, and by recruiting methyl-CpG binding proteins (MBDs) to methylated DNA 
together with histone modifying enzymes (Hendrich & Tweedie, 2003). This leads to 
configurational changes in chromatin histone proteins and a compact packing of 
nucleosomes that are implicated in transcriptional regulation, as well (Zheng et al., 2008; 
Cedar & Bergman, 2009). DNA methylation on cell-free DNA can be detected by 
methylation-sensitive PCR using bisulfite-converted DNA (Fig. 1, Table 1). 
CpG hypermethylation within the regulatory region of the π-class glutathione S-transferase 
gene (GSTP1) has been observed to be the most prevalent somatic genome abnormality in 
human prostate cancer, whereas this methylated GSTP1 is rarely detected in other organs. 
GSTP1 encodes an enzyme that acts as a carcinogen detoxifier by catalyzing conjugation 
reactions with reduced glutathione (Lee et al., 1994). Using a restriction endonuclease 
quantitative PCR technique, Bastian et al. (Bastian et al., 2005) addressed the question 
whether circulating cell-free DNA hypermethylation of GSTP1 can be evaluated as a 
prognostic biomarker for prostate cancer. They did not detect circulating hypermethylated 
GSTP1 in serum of men with a negative prostate biopsy, but they detected 
hypermethylation in 12% of men with clinically localized disease and 28% of men with 
metastatic cancer. Thus, they saw a continuing increase in DNA methylation during tumour 
progression. Moreover, they showed that men with clinically localized prostate cancer 
displaying CpG hypermethylation of GSTP1 in their preoperative serum were at significant 
risk to experience PSA recurrence within the following years after radical prostatectomy. 
These data suggest that hypermethylation of GSTP1 in blood may be an important DNA-
based prognostic serum biomarker for prostate cancer (Bastian et al., 2005). The same 
laboratory also assessed the hypermethylation profile of several other genes including 
multidrug resistance 1 (MDR1), endothelin receptor B (EDNRB), CD44, NEP (neutral 
endopeptidase), PTGS2, Ras association domain family 1 isoform A (RASSF1A), retinoic 
acid receptor-ß (RAR-ß) and ESR1 (estrogen receptor 1) in serum of men with clinically 
localized prostate cancer, hormone refractory metastatic disease or a negative prostate 
biopsy (Bastian et al., 2008). Hypermethylation of MDR1 was positive in 38% of the cases 
without PSA recurrence and in 16% of those with biochemical recurrence after radical 
prostatectomy. DNA hypermethylation of the other genes was not detected in the serum. 
No single gene was observed to be consistently hypermethylated in patients with hormone 
refractory disease. In serum from men with metastatic prostate cancer, hypermethylation 
was detected at MDR1 in 83%, EDNRB in 50%, RAR-ß in 39%, and NEP as well as RASSF1A 
in 17% of the cases. The hypermethylation of CD44, PTGS2 or ESR1 was not detected in any 
samples (Bastian et al., 2008). These finding show that along with the hypermethylation of 
GSTP1, the hypermethylation status of a defined panel of genes may represent convenient 
targets for men with prostate cancer. 
Using real-time PCR and sodium bisulfite-modified DNA, Payne et al. compared DNA 
methylation of the biomarkers GSTP1, RASSF2, histone 1H4K (HIST1H4K) and transcription 
factor AP2E (TFAP2E) in matched plasma and urine samples collected prospectively. The 
DNA methylation of the biomarkers in urine and plasma correlated significantly with each 
other. Surprisingly, the measurements of the biomarkers in urine were more sensitive for 
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prostate cancer detection than those in plasma (Payne et al., 2009). Ellinger et al. compared 
the CpG hypermethylation of GSTP1, TIG1, PTGS2 and Reprimo in prostate cancer and BPH 
patients using a restriction endonuclease real-time PCR. They detected a higher methylation 
frequency in serum of prostate cancer patients than in BPH patients. The hypermethylation 
in serum distinguished between both patient cohorts in a highly specific but less sensitive 
manner (Ellinger et al., 2008b).  
It is also possible to detect tumour-related altered histone modifications in blood of prostate 
cancer patients (Table 1). The utility of plasma levels of circulating bone-morphogenetic 
protein-6-specific (BMP6) mRNA and histone H3 lysine 27 trimethylation (H3K27me3) in 
discriminating metastatic prostate cancer from organ confined, local disease was evaluated 
at the end of therapy of the patients. Higher levels of BMP6 mRNA were found in the 
patients with metastases than in those with localized or local advanced disease. H3K27me3 
displayed an inverse distribution compared to BMP6 mRNA and was significantly lower in 
patients with metastatic disease than in those with localized or local advanced disease. This 
study provides evidence that post-treatment analysis of cBMP6 mRNA and H3K27me3 in 
plasma may be used to distinguish metastatic prostate cancer from organ confined, local 
disease (Deligezer et al., 2010). 
6. Combined genetic and epigenetic analyses of cell-free DNA 
Sunami et al. hypothesized that circulating multimarker DNA assays detecting both genetic 
and epigenetic markers in serum would be more useful in assessing prostate cancer patients. 
They examined DNA methylation of RASSF1, RAR-ß2 and GSTP1 using a methylation-
specific PCR assay and a panel of six microsatellite markers (D6S286 at 6q14, D8S261 at 
8p22, D8S262 at 8p23, D9S171 at 9p21, D10S591 at 10p15 and D18S70 at 18q23). The 
combination of these two DNA assays increased the number of prostate cancer patients 
positive for at least one marker and detected the presence of prostate cancer regardless of 
AJCC (American Joint Cancer Committee) stage or PSA concentration. When these DNA 
assays were combined with PSA measurements, they reached a sensitivity of 89%. This pilot 
study demonstrated that the combined circulating DNA multimarker assay may yield 
information independent of AJCC stage or PSA concentration (Sunami et al., 2009). 
7. Cell-free tumour DNA as a marker for circulating tumour cells 
Currently, PSA blood serum levels are measured repeatedly after the primary treatment of 
prostate cancer. However, approximately 25% of patients with clinically localized prostate 
cancer will eventually experience biochemical evidence of tumour recurrence after surgical 
resection of the primary tumour. A possible explanation for this clinical observation may be 
an early occult onset of tumour cell dissemination to the blood circulation in these men. 
Even if overt metastases are subsequently confirmed by current imaging technologies, such 
as bone scans, these patients have become already incurable (Pantel et al., 2009). Therefore, a 
biomarker indicating early spread of tumour cells as the potential seed for future metastases 
is highly desirable.  
The precise sources of tumour-related cell-free DNA in the peripheral blood are still 
unknown, but it has been postulated that this DNA may originate from primary and 
metastatic tumours. The most common view is that apoptotic and necrotic tumour cells shed 
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their DNA into the blood circulation. Dying circulating tumour cells (CTCs) may also 
contribute to the high levels of circulating DNA in the blood. This assumption provoked 
scientists to investigate the relation between cell-free tumour-related DNA and CTCs. 
Since different patterns of LOH may affect cancer progression toward metastases, we 
assessed the relationship of the occurrence of LOH on cell-free DNA with the presence of 
CTCs in peripheral blood of prostate cancer patients (Schwarzenbach et al., 2009). The 
presence of CTCs, which was detected by an epithelial immunospot assay, significantly 
correlated with the increase in LOH at the microsatellite markers D8S137, D9S171, and 
D17S855, which are located in the chromosomal regions of the cytoskeletal protein dematin 
(Lutchman et al., 1999), the inhibitor of the cyclin dependent kinase CDKN2/p16 
(Perinchery et al., 1999) and BRCA1 (Gao et al., 1995), respectively. Identification of LOH in 
these regions may contribute to a better understanding of early steps in the metastatic 
cascade in prostate cancer. Dematin is localized in the junctional complex bundling actin 
filaments in a phosphorylation-dependent manner. Its biological function is to regulate the 
cell shape, and changes in cell plasticity are thought to be important for the dissemination of 
tumour cells (Thiery & Sleeman, 2006). CDKN2/p16 is a protein of the cell cycle regulating 
the G1-S phase transition. It can be inactivated by mutations, deletions, or transcriptional 
silencing during pathogenesis of a variety of human malignancies and seems to be involved 
in the tumourigenesis of prostate cancer (Fernandez et al., 2002). BRCA1 has been 
implicated in a number of cellular processes including DNA repair and recombination, cell 
cycle checkpoint control, chromatin remodelling, ubiquitination, and apoptosis (Murray et 
al., 2007). Deletions in the BRCA1 gene have recently been implicated in metastatic spread 
and tumour progression in prostate cancer (Bednarz et al., 2010). 
A comparative genetic profiling of isolated PSA-positive CTCs and multifocal prostate tumour 
tissues was performed by Schmidt et al. They showed that the detection of LOH at the BRCA1 
locus in CTCs and primary tumours was associated with an early biochemical recurrence 
(Schmidt et al., 2006). In a recent study, Okegawa et al. determined for the first time the 
relation between CTCs detected on the CellSearch System and circulating tumour-related 
methylated DNA using a sensitive SYBR green methylation-specific PCR (Okegawa et al., 
2010). In blood of patients with hormone-refractory prostate cancer hypermethylation of 
adenomatosis polyposis coli (APC), GSTP1, PTGS2, MRD1 and RASSF1A was analyzed. With 
the exception of PTGS2, the presence of CTCs significantly correlated with the presence of 
methylated APC, GSTP1, MDR1 and RASSF1A. Patients with CTCs and methylated DNA in 
their blood had a shorter median overall survival time, which was significantly different from 
that of patients without either molecular markers or with one of both markers. In addition, 
patients with CTCs or tumour-related methylated DNA had a poorer outcome than patients 
without these blood markers, and patients with both markers had the worst outcome. These 
findings indicate the high relapse risk and aggressiveness of tumours in patients with high 
levels of CTCs and DNA methylation in the blood (Okegawa et al., 2010).  
Although the findings discussed above are still preliminary, they emphasize that cell-free 
tumour-related DNA may also stem from CTCs that have undergone cell death in the 
circulatory system.  
8. Circulating microRNAs 
MiRs are a class of naturally occurring small non-coding RNA molecules. They modulate 
post-transcriptionally the expression of numerous genes, such as tumor suppressor genes, 
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by binding sequence-specifically to their target mRNA and inhibiting their translation into 
proteins or degrading the mRNA. Mature miRs consist of 19 to 25 nucleotides and are 
derived from hairpin precursor molecules of 70-100 nucleotides. As half of human miRs are 
localized in fragile chromosomal regions, which may exhibit DNA amplifications, deletions 
or translocations during tumour development, their expression is frequently deregulated in 
cancer (Croce, 2009). MiRs have, therefore, important roles in repression of protein 
expression in cancer (Bartel, 2009). To date, studies on solid cancers (ovarian, lung, breast 
and colorectal cancer) reported that miRs are involved in the regulation of different cellular 
processes, such as apoptosis, cell proliferation, epithelial to mesenchymal transition and 
metastases (Heneghan et al., 2009). In blood, miRs appear highly stable, because most of 
them are included in apoptotic bodies, microvesicles, or exosomes and can withstand 
known mRNA degradation factors (Asaga et al., 2011; Kosaka et al., 2010). Quanitative real- 
time PCR can be used to measure circulating miRs with miR-specific TaqMan MicroRNA 
assays (Fig. 1, Table 1). 
Circulating miRs have recently been indicated as practicable and promising biomarkers for 
minimally invasive diagnosis in prostate cancer. Quantification of miR 21 targeting the 
tumour suppressor gene phosphatase and tensin homolog deleted (PTEN) and programmed 
cell death 4 (PDCD4) has been reported to be a useful biomarker for prostate cancer patients 
during disease progression (Zhang et al., 2010). Patients with hormone-refractory prostate 
cancer expressed higher serum miR 21 levels than those with androgen-dependent and 
localized prostate cancer. Androgen-dependent prostate cancer patients with low serum 
PSA levels had similar serum miR 21 levels to patients with localized prostate cancer or 
BPH. The highest serum miR 21 levels were found in hormone-refractory prostate cancer 
patients who were resistant to docetaxel-based chemotherapy when compared to those 
sensitive to chemotherapy. These findings suggest that miR 21 is an indicator of the 
transformation to hormone refractory disease and a potential predictor for the efficacy of 
docetaxel-based chemotherapy (Zhang et al., 2010). Quantification of miR-21 together with 
miR 141 and 221 revealed varying patterns in blood of the clinical subgroups. The 
differences in plasma between the control group and the patients were highly significant for 
miR 21 and 221 but not for miR 141. In patients diagnosed with metastatic prostate cancer, 
levels of all three miRs were significantly higher than in patients with localized and local 
advanced disease (Yaman Agaoglu et al., 2011). After screening of 667 miRs in serum 
samples from patients with metastatic and localized prostate cancer by microaarray 
analyses, five upregulated miRs were selected for further validation. Circulating miR 375 
and 141 turned out to be the most pronounced markers for high-risk tumours. Their levels 
also correlated with high Gleason score and lymph-node positive status. These observations 
suggest that the release of miR 375 and 141 into the blood circulation is associated with 
advanced cancer disease (Brase et al., 2010). 
Although there is only a few literatures on circulating miRs in blood of prostate cancer 
patients, the findings discussed above highlight their potential clinical utility (Table 1).  
9. Conclusion 
It took decades to attract attention to circulating cell-free nucleic as a surrogate for molecular 
analysis in the management of cancer patients, but their clinical relevance gains more and 
more in importance. Cell-free nucleic acids may be a reflection of the pathological processes 
during prostate cancer development, progression and metastasis. Besides these attributes, 
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nucleic acids play also important biological roles. An intriguing hypothesis, the so-called 
genometastasis hypothesis describes that extracellular DNA and RNA from cancer cells may 
transform normal cells. Thus, metastases could develop in distant organs as a result of 
horizontal transfer of dominant oncogenes released from the primary tumour by susceptible 
cells (Garcia-Olmo et al., 2004). Whether this biological function has relevance in human 
blood in prostate cancer patients is an aspect to be considered in the future.  
Since tumour-associated nucleic acids are easily accessible from plasma/serum and may 
be derived from several different sources, e.g. primary tumour, lymph nodes or CTCs, 
their detection could provide more information on prostate tumour biology. Although 
there is a number of biomarkers, e.g. PSA, commonly used for prostate cancer, these 
markers are also elevated in BPH patients, and their levels are dependent on prostate 
volume and age of the men. To date, the screening of cancer patients relies on early 
diagnosis, precise tumour staging, and monitoring of therapies. Histological evaluation of 
tumour tissues obtained from biopsies is the gold standard of diagnosis at present. 
Minimally invasive blood analyses of cell-free nucleic acids could have the potential to 
complement the existing biomarkers, such as PSA, and current clinical methods. These 
minimally invasive assays could serve as a “liquid biopsy” that can be repeated many 
times in an individual patient to assure a real-time monitoring of the disease course and 
assess the efficacy of anti-cancer therapies. In combination with the detection of CTCs, 
this assay might allow following metastatic progression and to predict the outcome of 
prostate cancer patients. The emerging biological role of miRs in the regulation of 
different cellular processes, e.g. apoptosis, cell proliferation, tumour progression, 
epithelial-mesenchymal transition and metastasis suggests that they may have a great 
potential as novel blood-based biomarkers and may also be considered as future 
therapeutic targets. 
However, there are also some drawbacks. As the prevalence of wild type nucleic acids in 
blood hampers the genetic analyses of cell-free tumour DNA, better extraction procedures 
are required. This also implicates that the pre-analytical parameters, such as blood 
collection, processing of plasma or serum, storage and accurate clinical conditions need to 
be improved. The quantification of cell-free nucleic acids using different methods ia a 
further problem. To date, no approach has been developed that is consistent, robust, 
reproducible, and validated on a large-scale prostate cancer patient population. If these 
problems could be solved, these issues would provide better universal standardization for 
comparison of results and address clinical utility of the assays. Another issue is that after 
extraction of nucleic acids, different assays varying in assay sensitivity and specificity are 
used for analysis. A standardized PCR-based assay is needed in validating clinical 
biomarkers. This implicates that the slowed down progress of new cancer blood-based 
biomarkers in the last decade could be pushed.  
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The present textbook highlights many of the exciting discoveries made in the diagnosis and treatment of
prostate cancer over the past decade. International thought leaders have contributed to this effort providing a
comprehensive and state-of-the art review of the signaling pathways and genetic alterations essential in
prostate cancer. This work provides an essential resource for healthcare professionals and scientists
dedicated to this field. This textbook is dedicated to the efforts and advances made by our scientific
community, realizing we have much to learn in striving to some day in the not too distant future cure this
disease particularly among those with an aggressive tumor biology.
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